Category
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Stem Cells & Wnt
- Hippo
- Ubiquitin
- Neuronal Signaling
- NF-κB
- GPCR & G Protein
- Endocrinology & Hormones
- Transmembrane Transporters
- Metabolism
- Proteases
- Microbiology
- Others
Archives
PI3K
Small molecule 2,3-DCPE induces S phase arrest by activating the ATM/ATR-Chk1-Cdc25A signaling pathway in DLD-1 colon cancer cells
18 views | Oct 29 2020
Bingjun Bai et al. suggested that 2,3-DCPE caused DNA damage in colon cancer cells and that 2,3-DCPE-induced S phase arrest was associated with the activation of the ATM/ATR-Chk1-Cdc25A pathway. [Read the Full Post]
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
17 views | Oct 22 2020
Fabian Lang et al.thought that combined inhibition of PI3K and mTOR inhibited a clinically meaningful driver pathway in a small subset of patients with ALL, with no benefit in patients with AML. [Read the Full Post]
HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer
17 views | Oct 20 2020
Peter Kok-Ting Wan et al. provided that BEZ, but not GSK, could abolish Nurr1-enhanced radioresistance, suggesting its potential value for radiosensitizing CSLCs in the clinical setting. [Read the Full Post]
The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
18 views | Oct 10 2020
Yangjiong Xiao et al. concluded that GSK458 might serve as an attractive candidate to treat ovarian cancer. [Read the Full Post]
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma
19 views | Oct 05 2020
Monique Bernard et al. suggested a broader application for this combination therapy that could be promptly translated to in vivo studies. [Read the Full Post]
Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling
21 views | Oct 05 2020
Dong-Shan Zhu et al. supported the rationale for using omipalisib as a therapeutic approach in ESCC patients. [Read the Full Post]
Tyrosyl-DNA phosphodiesterase and the repair of 3'-phosphoglycolate-terminated DNA double-strand breaks
0 views | Sep 03 2020
Tong Zhou et al. suggested a role for TDP1 in repair of 3'-PG double-strand breaks in vivo. [Read the Full Post]
Inhibition of DNA-PKcs activity re-sensitizes uveal melanoma cells to radio- and chemotherapy
43 views | Sep 03 2020
Bingjie Zhang et al. demonstrated increased DNA double strand break repair as a mechanism of resistance to ionizing radiation and Selumetinib, and identified DNA-PKcs as a promising target for radio-and chemotherapy in UM patients. [Read the Full Post]
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
34 views | Aug 17 2020
Victor McPherson et al. proposed that given the modest clinical activity and substantial toxicity of buparlisib, future trials of PI3K inhibitors in patients with UC should focus on isoform-selective PI3K inhibitors in genomically selected patients. [Read the Full Post]
The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia
37 views | Aug 17 2020
Chie Ishikawa et al. showed that CUDC-907 might be a potential therapeutic agent for ATL. [Read the Full Post]
